BW 534U87

Drug Profile

BW 534U87

Alternative Names: 534U87

Latest Information Update: 17 Mar 1999

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 17 Mar 1999 Discontinued-Clinical for Epilepsy in United Kingdom (PO)
  • 26 Feb 1997 Phase-II clinical trials for Epilepsy in United Kingdom (PO)
  • 25 Mar 1996 Phase-I clinical trials for Epilepsy in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top